Supplementary Table S2 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer

Supplementary Table S2 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer

<p>Supplementary Table S2. Results of single-sample gene set enrichment analysis (ssGSEA) of transcriptomic profiles from HCC-1428 and HCC-1428/LTED cells.</p>

Αποθηκεύτηκε σε:

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριος συγγραφέας:	Nicole A. Traphagen (16677391) (author)
Άλλοι συγγραφείς:	Gary N. Schwartz (16005870) (author), Steven Tau (16677394) (author), Alyssa M. Roberts (16677397) (author), Amanda Jiang (15117790) (author), Sarah R. Hosford (16677400) (author), Jonathan D. Marotti (16005879) (author), Abigail E. Goen (16677403) (author), Bianca A. Romo (16677406) (author), Anneka L. Johnson (16677409) (author), Emily-Claire K. Duffy (16677412) (author), Eugene Demidenko (16005894) (author), Paul Heverly (16677415) (author), Yaron Mosesson (16677418) (author), Shannon M. Soucy (16005888) (author), Fred Kolling (16005891) (author), Todd W. Miller (16005897) (author)
Έκδοση:	2025
Θέματα:	Cancer Therapeutic Research and Development Breast Cancer Drug Mechanisms Cellular responses to anticancer drugs Drug Resistance Reversal of drug resistance
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια

Supplementary Table S1 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer
ανά: Nicole A. Traphagen (16677391)
Έκδοση: (2025)

Data file S1 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
ανά: Alex C.H. Liu (14961921)
Έκδοση: (2025)

Data file S2 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
ανά: Alex C.H. Liu (14961921)
Έκδοση: (2025)

Data file S3 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
ανά: Alex C.H. Liu (14961921)
Έκδοση: (2025)

Data file S4 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
ανά: Alex C.H. Liu (14961921)
Έκδοση: (2025)

Data file S5 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
ανά: Alex C.H. Liu (14961921)
Έκδοση: (2025)

Table S1 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
ανά: Alex C.H. Liu (14961921)
Έκδοση: (2025)

Supplementary Data from Pharmacological Targeting of Androgen Receptor Elicits Context-Specific Effects in Estrogen Receptor–Positive Breast Cancer
ανά: Lixuan Wei (14962431)
Έκδοση: (2025)

Figure S1 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
ανά: Dahihm Kim (16546203)
Έκδοση: (2025)

Figure S2 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
ανά: Dahihm Kim (16546203)
Έκδοση: (2025)

Figure S3 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
ανά: Dahihm Kim (16546203)
Έκδοση: (2025)

Figure S4 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
ανά: Dahihm Kim (16546203)
Έκδοση: (2025)

Figure S5 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
ανά: Dahihm Kim (16546203)
Έκδοση: (2025)

Table S1 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
ανά: Dahihm Kim (16546203)
Έκδοση: (2025)

Table S3 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
ανά: Dahihm Kim (16546203)
Έκδοση: (2025)

Supplementary Table 1 from Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor–Positive Metastatic Breast Cancers
ανά: Juliana Navarro-Yepes (17079059)
Έκδοση: (2025)

Table ST1 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
ανά: Ossia M. Eichhoff (14964145)
Έκδοση: (2025)

Table ST2 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
ανά: Ossia M. Eichhoff (14964145)
Έκδοση: (2025)

Table ST3 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
ανά: Ossia M. Eichhoff (14964145)
Έκδοση: (2025)

Table ST4 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
ανά: Ossia M. Eichhoff (14964145)
Έκδοση: (2025)

Table ST5 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
ανά: Ossia M. Eichhoff (14964145)
Έκδοση: (2025)

Table ST6 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
ανά: Ossia M. Eichhoff (14964145)
Έκδοση: (2025)

Table ST7 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
ανά: Ossia M. Eichhoff (14964145)
Έκδοση: (2025)

Table ST8 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
ανά: Ossia M. Eichhoff (14964145)
Έκδοση: (2025)

Table ST9 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
ανά: Ossia M. Eichhoff (14964145)
Έκδοση: (2025)

Supplementary Table S1 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
ανά: Yufang Bao (15386826)
Έκδοση: (2025)

Supplementary Table S2 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
ανά: Yufang Bao (15386826)
Έκδοση: (2025)

Supplementary Table S3 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
ανά: Yufang Bao (15386826)
Έκδοση: (2025)

Supplementary Table S4 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
ανά: Yufang Bao (15386826)
Έκδοση: (2025)

Supplementary Table S5 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
ανά: Yufang Bao (15386826)
Έκδοση: (2025)

Supplementary Data 1 from Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer
ανά: Kavya Ramkumar (16474203)
Έκδοση: (2025)

Figure 1 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
ανά: Milana A. Bergamino (15038015)
Έκδοση: (2025)

Figure 2 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
ανά: Milana A. Bergamino (15038015)
Έκδοση: (2025)

Figure 3 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
ανά: Milana A. Bergamino (15038015)
Έκδοση: (2025)

Figure 4 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
ανά: Milana A. Bergamino (15038015)
Έκδοση: (2025)

Figure 5 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
ανά: Milana A. Bergamino (15038015)
Έκδοση: (2025)

Figure 6 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
ανά: Milana A. Bergamino (15038015)
Έκδοση: (2025)

Supplementary Movie S1 from Anticoagulants Enhance Molecular and Cellular Immunotherapy of Cancer by Improving Tumor Microcirculation Structure and Function and Redistributing Tumor Infiltrates
ανά: Fang Wei (15057172)
Έκδοση: (2025)

Supplementary Movie S2 from Anticoagulants Enhance Molecular and Cellular Immunotherapy of Cancer by Improving Tumor Microcirculation Structure and Function and Redistributing Tumor Infiltrates
ανά: Fang Wei (15057172)
Έκδοση: (2025)

Supplementary Movie S3 from Anticoagulants Enhance Molecular and Cellular Immunotherapy of Cancer by Improving Tumor Microcirculation Structure and Function and Redistributing Tumor Infiltrates
ανά: Fang Wei (15057172)
Έκδοση: (2025)

Cannot write session to /tmp/vufind_sessions/sess_hnfg59fp9cin1s09ccu5btv62j